Nuveen LLC Invests $258,000 in Nkarta, Inc. $NKTX

Nuveen LLC bought a new position in shares of Nkarta, Inc. (NASDAQ:NKTX) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 140,113 shares of the company’s stock, valued at approximately $258,000. Nuveen LLC owned approximately 0.20% of Nkarta as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of NKTX. Invesco Ltd. boosted its stake in shares of Nkarta by 478.4% in the first quarter. Invesco Ltd. now owns 69,396 shares of the company’s stock worth $128,000 after acquiring an additional 57,399 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Nkarta by 36.3% in the first quarter. Deutsche Bank AG now owns 58,812 shares of the company’s stock worth $108,000 after acquiring an additional 15,655 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Nkarta by 18.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 147,551 shares of the company’s stock worth $271,000 after acquiring an additional 22,538 shares during the last quarter. Monaco Asset Management SAM acquired a new stake in shares of Nkarta in the first quarter worth approximately $1,496,000. Finally, CWM LLC boosted its stake in shares of Nkarta by 3,437.3% in the first quarter. CWM LLC now owns 28,157 shares of the company’s stock worth $52,000 after acquiring an additional 27,361 shares during the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Stock Up 6.1%

NASDAQ:NKTX opened at $2.26 on Friday. Nkarta, Inc. has a 52 week low of $1.31 and a 52 week high of $6.63. The company has a market capitalization of $160.53 million, a P/E ratio of -1.53 and a beta of 0.76. The stock’s fifty day moving average is $2.05 and its two-hundred day moving average is $1.89.

Nkarta (NASDAQ:NKTX) last posted its earnings results on Tuesday, August 12th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. Sell-side analysts anticipate that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. William Blair reaffirmed a “market perform” rating on shares of Nkarta in a research note on Thursday, May 15th. Stifel Nicolaus dropped their price objective on shares of Nkarta from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, August 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Nkarta in a research note on Wednesday, August 13th. Mizuho dropped their price objective on shares of Nkarta from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, June 10th. Finally, Wall Street Zen raised shares of Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $13.60.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.